ImmunoGen, Inc. Announces Webcast of Presentation at the 31st Annual J.P. Morgan Healthcare Conference
January 02 2013 - 5:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops anticancer therapeutics using its Targeted Antibody
Payload (TAP) technology and antibody expertise, today announced
that Daniel Junius, President and CEO, will present at the upcoming
31st Annual J.P. Morgan Healthcare Conference in San Francisco. The
presentation is scheduled for 8:00 am PT on January 7, 2013 and
will include information about IMGN289, which is on track to become
the fourth wholly owned ImmunoGen compound to advance into clinical
testing.
A webcast of this presentation will be accessible live through
the “Investor Information” section of the Company’s website,
www.immunogen.com; a replay of the presentation will be available
at the same location for two weeks.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its TAP technology together with the Company’s expertise in
monoclonal antibodies and tumor biology. A TAP compound uses a
tumor-targeting monoclonal antibody to deliver one of ImmunoGen's
purpose-developed cancer-killing agents specifically to tumor
cells. Ten TAP compounds are now in clinical testing, of which
three are wholly owned by the Company. Marketing applications for
trastuzumab emtansine (T-DM1), the most advanced compound using
ImmunoGen's TAP technology, are under review in the US and Europe.
Roche is developing this compound globally under an agreement
between ImmunoGen and Genentech, a member of the Roche Group. More
information about ImmunoGen can be found at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2023 to Aug 2024